Northern Ireland is investing £11.7m in a pharmaceutical innovation programme intended to help businesses develop and commercialise products by providing access to specialist university facilities, manufacturing expertise and research capability.
The iPHARMA programme will be delivered by Queen’s University Belfast and Ulster University and funded through UK Research and Innovation’s Local Innovation Partnerships Fund.
It is the first project announced from a £30m allocation to the Belfast-Derry Innovation Corridor, connecting research capability in Northern Ireland’s two largest cities with businesses seeking to turn scientific development into commercially viable products.
The programme addresses a persistent challenge in life sciences. Promising research can advance through early discovery before encountering significant barriers when businesses need to validate manufacturing processes, scale production and meet the technical requirements associated with regulated pharmaceutical products.
Smaller companies are particularly exposed because specialist equipment and scientific expertise can be expensive to build internally. Shared university infrastructure can reduce the amount of capital required before a business knows whether a product can progress successfully.
The investment therefore sits between academic research and industrial policy. Rather than funding research alone, iPHARMA is designed around the difficult process of moving scientific ideas towards products that can be manufactured and sold.
Northern Ireland already has an established pharmaceutical and diagnostics base supported by university research and a broader life-sciences workforce. The new programme is intended to strengthen the infrastructure connecting those elements.
Commercialisation capacity has become a more prominent concern across the UK innovation economy. Universities generate significant research and intellectual property, but economic value depends on businesses being able to finance development, recruit management, scale manufacturing and reach regulated markets.
Life sciences magnifies those requirements because product development can involve lengthy timelines, expensive validation and strict quality standards. Laboratories alone are insufficient; companies also require manufacturing knowledge, regulatory expertise and access to industry networks.
iPHARMA’s university partnership gives participating businesses access to complementary capabilities from Queen’s and Ulster while reducing the need to navigate separate institutional programmes for different parts of the development process.
The investment follows broader efforts to improve growth capital and innovation funding in Northern Ireland. The Investment Fund for Northern Ireland recently passed £100m in total investment, combining public programme capital with additional private finance.
Funding and commercialisation infrastructure address different bottlenecks. A company with capital can still struggle without specialist facilities, while strong research infrastructure has limited economic impact if businesses cannot finance subsequent stages of growth.
iPHARMA adds another component to the region’s attempt to build a more complete route from research through to commercial scale.
Stronger industry participation can also feed back into university research. Businesses bring manufacturing and market problems into academic environments, while universities can provide expertise that would be difficult for smaller companies to maintain permanently.
The £11.7m commitment will not alone determine whether Northern Ireland produces more pharmaceutical businesses capable of reaching international scale. Results will depend on company participation, the quality of projects entering the programme and whether those businesses can secure follow-on capital after technical development.
The programme nevertheless targets a recognisable gap between scientific innovation and repeatable commercial production. Reducing the cost and complexity of crossing that gap could support new products while adding depth to Northern Ireland’s existing pharmaceutical and life-sciences base.
You must be logged in to post a comment.